Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.76 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.65 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.79 |
| ▸ | KDR | P35968 | 2/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | BLVRB | P30043 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | THRB | P10828 | 3/20 | 0.76 |
| ▸ | RECQL | P46063 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | TNF | P01375 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL8703147 | 1.00 | MEN1 (0.79) | MEN1KMT2AKDRPDE4ABLVRB | |
| SCHEMBL4326144 | 0.93 | MEN1 (0.79) | MEN1KMT2AKDRPDE4ABLVRB | |
| SCHEMBL4326140 | 0.93 | MEN1 (0.79) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL4096909 | 0.91 | MEN1 (0.66) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL28125721 | 0.90 | MEN1 (0.74) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL28125720 | 0.90 | MEN1 (0.74) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29385751 | 0.89 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25118 | 0.89 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL25119 | 0.89 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB | |
| Olsalazine SCHEMBL29378994 | 0.89 | MEN1 (1.00) | MEN1KMT2AKDRPDE4ABLVRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311971-A | Anti- TL1A/ anti-tnf-alpha Bispecific antigen binding proteins and application thereof | 美国安进公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-106459182-A | Tandem FAB immunoglobulins and uses thereof | 岸迈生物科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-103025758-B | IL-1 binding proteins | ABBVIE 公司 | 2017-01-18 | — | — | CN | disclosed |
| US-20140234410-A1 | COMBINATION PRODUCTS | SIGMOID PHARMA LTD. (IE) | 2014-08-21 | — | — | US | disclosed |
| EP-2322146-B1 | Microcapsule formulations comprising two pharmaceutically active ingredients | SIGMOID PHARMA LTD (IE) | 2012-12-12 | — | — | EP | disclosed |
| EP-2444071-A1 | Minicapsule formulations | Sigmoid Pharma Limited (IE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2322146-A2 | Microcapsule formulations comprising two pharmaceutically active ingredients | Sigmoid Pharma Limited (IE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2156826-A1 | Microcapsule formulations comprising two pharmaceutically active ingredients | Sigmoid Pharma Limited (IE) | 2010-02-24 | — | — | EP | disclosed |
| EP-2153824-A1 | Seamless multiparticulate formulations | Sigmoid Pharma Limited (IE) | 2010-02-17 | — | — | EP | disclosed |
| US-20080020018-A1 | Combination Products | SIGMOID PHARMA LIMITED (IE) | 2008-01-24 | — | — | US | disclosed |
| EP-1811979-A2 | MICROCAPSULES COMPRISING A METHYLXANTHINE AND A CORTICOSTEROID | Sigmoid Biotechnologies Limited (IE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1499303-A4 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | MILLER FRED H (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1802287-A2 | MINICAPSULE FORMULATIONS | Sigmoid Biotechnologies Limited (IE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006035418-A2 | MICROCAPSULES COMPRISING A METHYLXANTHINE AND A CORTICOSTEROID | SIGMOID BIOTECHNOLOGIES LIMITED (IE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035416-A2 | MINICAPSULE FORMULATIONS | SIGMOID BIOTECHNOLOGIES LIMITED (IE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1499303-A2 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | Miller, Fred H. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003086267-A2 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | MILLER FRED H (US) | 2003-10-23 | — | — | WO | disclosed |
| US-5837289-A | ORGANOGEL COMPRISING FATTY ACID PHOSPHOLIPID EMULSIFYING AGENT AND FATTY ACID OR ESTER THEREOF | IMPRIMIS PHARMACEUTICALS, INC. | 1998-11-17 | — | — | US | disclosed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | disclosed |